Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes I had just under 300,000 shares at a average of 20 cents.
No chance. He took investor mon eye at .15
All sounds good uncle Mike. You have ba$$s. I will hold and ride your coattails.
Thanks again for you insight.
Be interesting to see if the CEO bought the dip today and files a form 4
We will find out on Wednesday.
I have been down $700,000 on paper, on one stock.
You get use to the wild swings after a while on OTC.
Being diversified helps a lot, Never put all the eggs in one basket.
There are no, no risk investments. One of the 10 largest US banks failed this month.
Poof just like, it was dead. Silicone Valley Bank.
Risk reward wise, this is a great one. Today's news does not change my mind, it only reminds me how many wolves and sheep there are gaming the stock market, just like claims made that the FDA games the drug winners and losers, there are games played to milk retail of their shares..
I never sell shares at loss. That is just my style. I also never buy shares in company I am not willing to buy more on dips.
L-2 on $RVVTF was all screwed up this morning and short MMs (convertible MMs even) were all over it, and it was hard to tell what was going on with most OTC stocks this morning. It took over 2 hours for most of the L-2 OTC stock data mess to clear up.
I started buying more RVVTF shares about 30 minutes ago.
There is a huge chart gap overhead formed at the open today, that needs to fill, back up to at least .068 range
No one should have sold the bottom today, that is a rookie mistake.
Bid support seems to be strong at the .037 Fib range now.
The news left a lot of future rally doors open for solid upside. Some body, BP(?) Hedge Funds(?) wanted this stock way down and got it down 70% off the price RVVTF raised 4.3 Million dollars at, namely at .10/share
We can speculate later on what the 2nd half of the PR says that is bullish, lots of bullish options listed.
https://www.proactiveinvestors.com/companies/news/1009552/revive-therapeutics-provides-update-of-phase-3-clinical-study-for-bucillamine-in-treatment-of-covid-19-1009552.html
Be interesting to see if the CEO bought the dip today and files a form 4.
My opinions on RVVTF have not changed. In fact it is a better buy now than before, who would not buy at 70% off the price they just raised 4.3 Million dollars at? or 95% off the 2 year high?
The FDA trial is still underway.
Google dollar cost averaging folks.
I have never owned any shares in this security just seen it going down since last October from .30 to where it is now
You should never dump when news causes a dump. Remember there are lots of holders with millions of shares. Should at least move up from these levels over the next few days with more clarity. Let the dump die out. They have one than one item in the pipeline.. Let the price recoup let your emotions subside before jumping out. Calm down and wait for a better price before selling. That’s my opinion.
Your down 51,000.00 dollars?
Cannacord is probably in the process of renting a bunch of nooses right now.
Yep. So said for all who took the pump
Imagine those investors who bought the offering at a premium
govprs, BTW unfortunately your .05 prediction was wrong! LOL
Dont know if it will help but BMT on reddit said he is down 117,000......misery loves company.
wise man, there is still a lot of value in this stock once all the dust settles from this disappointment.
Hotel Delta.....Im going to hold as I need .20 to break even, down 51,000 right now.
Rubberneck2 I feel your pain, this is money that I had no business throwing away especially on a penny stock. I never learn my lesson but now that I am such deep shit with money issues, I am done with investing. These days it's all short sellers and day traders who profit. Long term investors are getting screwed big time. Since the company is still afloat, maybe just maybe something good will happen for us. At this point it doesn't pay to sell. I'll just wait it out until the end of the year. GLTU and all who thought this shitty little company would make us some serious money.
Rubber.....yep,I was up nice when this shot up before could of sold but was
greedy (as usual) and blew it......I did the same with another little sub penny
stock I bought about the same time as RVVTF.....bought in at 0.0004 it ran to 4 cents
and I was up 15,000 on a 250 investment..did I sell....NOOOOO and now its back
down to 0.0003.....this stuff isnt for me,I will hold and see what happens,hope it
maybe get back to .15 - .20 and I can break even at some point.
Well said. Penny stocks are always a risk as all of you know. Ups and downs are normal. I'm still hanging on, won't sell, no reason too I don't need the loss until the end of the year. I still have hope I can at least recover my loss by the end of the year.
Noble words in the face of a shitty result It's only. Within 7 months this stock put me in a position to pay off my mortgage and all other debt too. Greed prevented me from doing so. And here we are, with no one to blame but ourselves.
Lessons learned.
Sooooo. No MF monogrammed sweatpants now?
HAHAHAHAHAHAHA!!!!!
I have no one to blame but myself,really thought they had something and as I said
im ride or die.....well im dead.
Don’t worry ric said he was buying all shares under a nickel
Lost a shit ton of money on this crap. I shoulda, coulda woulda sold a long time ago. I think I am done with the stock market for good. It's never a good time to lose money especially now!! So upset and angry.
just sold. not even joking. left a few "just-in-case". i afforded myself more than i could lose to risk. not having fun
So thats it......probalby with the dump thats coming will just stay and see if I can at least break even in a few years
unless they go bankrupt.....thats enough of stocks for me,not my thing.
......"the Study was not designed to take into account all of the symptom assessments and supporting data outlined in the FDA guidelines to warrant a primary symptom-based endpoint for COVID-19 studies".
As a layman. I read that as "even though guilines were in place, we ignored them and did our own thing."
Am I wrong?
Well, can't sell, too much invested in this stock. I'll have to wait it out and if this continues I'll sell later in the year and take the loss and mend my wounds.
They are clueless. They don’t know what is in the stockholders best interest
I expect lawsuits
Seriously what is the idea now we all gonna cut our loss? File a lawsuit? Wait it out for MF to save the day last minute?
So unfortunately (or maybe fortunately) our trial did not take into account how many boogers would be left in patients nose after the 2 weeks is up
News out rvv sticking with original end points.
Hey bud did you ever try taking a reasonable and therapeutic amount instead of recklessly eating 30 at a time? No? Well I've got news for you about benadryls
For this latest submission they were definitely communicating re the type c meeting but prior to that there may have been but imo it would have been limited.
As I previously mentioned, either the rvv med team is simply inept at comprehending what the fda requires, or the fda is constantly moving the goal posts re what they require for approval of the ep submission.
I can think of no reasons why rvv would deliberately want to continuously delay the process by providing substandard submissions.
There is no present need for additional trial data, nor do I believe that any data from dr fahy's research at ucsf will have little impact on the ep change request so a desire for delays is simply not there.
I am tending to believe that the fda (among others) is at the root of this obvious farce and that the link below possibly indicates the reason why................
FDA authorizes Pfizer’s Covid omicron booster as fourth shot for kids under 5
That mushroom will make you nuts ,it grows here wild in pastures where I live we used to eat them raw about 30 at a time and it was like dropping 3 hits of LSD ,there is no good use for them ,they have no good effects on the brain at all except make you super paranoid
As much as we value our Psilocybin asset, our priority should be on maximizing profits for our shareholders. With a hefty $10 million investment in Psilocybin, it's time for us to consider all options, including a possible sell-out to a larger pharmaceutical company or selling it back to PharmaTher. Our limited working capital forces us to focus on what's profitable for the company. After all, we cannot afford to support the research and development of both Psilocybin and Bucillamine. It's clear from the costs associated with research on Psilocybin-based formulations, which amounted to $637,790 in just six months is higher than bucillamine. That we need to manage our capital more prudently. As we move forward, MF need to make strategic decisions that will benefit our company and our investors.
only money--thought you might enjoy article--I just saw today but RE confirms the viral "hideout"
https://www.ndtv.com/world-news/viruses-hiding-in-body-for-months-could-explain-lingering-long-covid-3858850
No one knows whether the coronavirus or its remnants remain in everyone who's had Covid, or if it's just a group of patients,
--eventually IMHO the long covid patients will fall into 2 groups. 1 group that has remnants or viral persistence. These will need to remove the persistence before any Rx can really help
and #2--a group that their immune system has turned on itself/gone haywire and either presented new symptoms or reactivated old bloodstream /prev virus/symptoms. These will need Rx tailored to which biomarker is inflammed
Even a relatively small number of infected cells could provoke the immune system to produce inflammation, blood clots and other problems associated with long Covid, according to Amy Proal, co-founder of PolyBio Research Foundation
Indeed. The effort by BP funded hedge funds here is way too obvious. Time for MF to raise ante to BILLIONs for a buy out. And to ask the Federal trade commission to investigate BP's miss use of hedge funds to short small drug stocks like $RVVTF.
Game on
If there was a back and forth between the fda and revive we would know what endpoint we should have chose. So this belief that there was communication is bs. Just stop with that. You are embarrassing yourself.
Dumbfounding. One would think after the first correction the FDA would say no we need XYZ. Very bizarre this vague back and forth. As stated either RVVTF is truly inept. Or the FDA is crooked. Both are believable IMO
Perhaps they don’t have any idea on how long it will take to reply?
Unlike previous News Releases this latest one doesn't provide a "goal date". It would be nice to have something to aim for even if the target date is missed, once again.
Weren’t they in constant communications with the FDA?
Something doesn’t seem to make sense
Followers
|
338
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
36616
|
Created
|
02/23/17
|
Type
|
Free
|
Moderators Classic Warrior |
Scientific Rationale of Bucillamine
Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to restore antioxidant and to reduce the activity of cellular glutathione 2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via restoration of glutathione activity and other anti-inflammatory activity, to lessen the negative consequences of SARS-CoV2 infection in the lungs.
| Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body's own natural pathways of absorption while offering a contemporary approach to consumption. Psilocin Pharma also has strong relationships with specific lab partners in certain areas like Brazil, where these formulations are legally approved and plan to sell products in these jurisdictions. | |
| |
Mental Health (Depression, PTSD & Anxiety)
|
Supplements for Brain Health & Cognitive Enhancement
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |